Clinical trial
A Phase 1, Multi-center, Single-dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of Golcadomide (BMS-986369) in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
NCT07763418 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multi-center, Single-dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of Golcadomide (BMS-986369) in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 8, 2026
- Completion date
- December 28, 2026
- Enrollment
- 30 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.